Collegium Pharma (COLL) Misses Q4 EPS by 1c

Collegium Pharma (Nasdaq: COLL) reported Q4 EPS of ($0.46), $0.01 worse than the analyst estimate of ($0.45).

Financial Outlook

Based on our current operating plans, Collegium expects that its existing cash resources, along with the net proceeds of its January 2016 follow-on offering, will fund its operations into 2018.

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.

You May Also Be Interested In

• Home Depot beats estimates, reaffirms fiscal 2026 guidance
• Micron Technology (MU) Reiterated at Buy by UBS as Investor Positioning Skews Cautious
• Baidu (BIDU) Misses Q2 EPS by 262c, misses on revenue